Ledesma, J., Ma, J., Zheng, P.,
et al. (2021). Interferon-gamma release assay levels and risk of progression to active tuberculosis: a systematic review and dose-response meta-regression analysis.
BMC Infect Dis, 467.
https://doi.org/10.1186/s12879-021-06141-4Meermeier, E., Lewinsohn, D. (2018). Early clearance versus control: What is the meaning of a negative tuberculin skin test or interferon-gamma release assay following exposure to Mycobacterium tuberculosis? Faculty Rev-664. doi:10.12688/f1000research.13224.1
Pai, M., Denkinger, C., Kik, S., et al. (2014). Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev., 27(1):3-20. doi:10.1128/CMR.00034-13.
Ra, S., Lyu, J., Choi, C., et al. (2011). Distinguishing tuberculosis from Mycobacterium avium complex disease using an interferon-gamma release assay. Int J Tuberc Lung Dis., 15(5):635-640. doi:10.5588/ijtld.10.0485.
Stockbridge, E., Loethen, A., Annan, E., & Miller, T. (2020) Interferon gamma release assay tests are associated with persistence and completion of latent tuberculosis infection treatment in the United States: Evidence from commercial insurance data.
PLOS ONE, 15(12): e0243102.
https://doi.org/10.1371/journal.pone.0243102